Up­dat­ed: One down, one to go: Ar­cutis' re­pur­posed As­traZeneca drug clears first PhI­II eczema tri­al

Ar­cutis Bio­ther­a­peu­tics is on a roll. Months af­ter launch­ing its top­i­cal for­mu­la­tion of an old As­traZeneca drug in plaque pso­ri­a­sis, the com­pa­ny is tout­ing pos­i­tive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER